Follow the entities shaping the evidence.

…reast tumors than T-DXd.Conclusions The advanced ADC, utilizing Exatecan and a super-hydrophilic polymer carrier, achieved ultra-high dr…

…metastases and extensive-stage disease. Despite the approval of tarlatamab and ongoing development of DLL3- or B7-H3-targeted ADCs, tumor …

…rm and shows significantly reduced cytokine release.Conclusions CX-908 shows strong anti-tumor efficacy and an improved tolerability p…

…successful bispecific antibodies, albeit primarily for treating blood cancers. TCEs provide a strong signal 1 for redirecting polyclonal T ce…

…inical application has been challenged by significant toxicity. CT-P72/ABP-102 is a tetravalent bispecific HER2 and CD3 T-cell engager enginee…

…systems we currently employ. To address this issue we generated Acute Myeloid Leukemia (AML) and Ovarian Cancer (OC) models using three different mous…

…1b, HLA-DR) on AML cells both in vitro and in vivo. Compared to azacitidine as the benchmark hypomethylating agent, the intravenous injecti…

…ivo, thereby validating these CD3 VHHs as an ideal platform for TCE engineering.…

…sis, achieved superior tumor growth inhibition and outperformed mirvetuximab soravtansine. Our data highlights the therapeutic potential and tolerability…

…and results In vitro, IBDV infects and replicates within murine GBM cells and patient-derived GBM stem cells, inducing direct oncol…

…ce (NICE) in 2020. These briefings serve as the trigger for the NICE Technology Assessment process. Data on the medicines’ submissio…

… School of Medicine, Shanghai, China.Participants A total of 89 ischaemic heart failure (IHD) patients confirmed by symptoms, echocardiography and coro…